Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch

NCT02697045 is registered in ClinicalTrials.gov with Abdi İbrahim Otsuka as lead sponsor.

NCT NCT02697045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02697045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch
Lead sponsor
Abdi İbrahim Otsuka
Phase
Phase 4
Overall status
Completed
Start date
January 4, 2017
Completion date
March 31, 2018
Enrollment
23 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia